Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Risk factors for chronic kidney disease after chemotherapy for testicular cancer.

Inai H, Kawai K, Ikeda A, Ando S, Kimura T, Oikawa T, Onozawa M, Miyazaki J, Uchida K, Nishiyama H.

Int J Urol. 2013 Jul;20(7):716-22. doi: 10.1111/iju.12017. Epub 2012 Nov 27.

2.

Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?

Suer E, Mermerkaya M, Gülpınar Ö, Afandiyev F, Baltacı S, Türkölmez K, Bedük Y.

J Urol. 2013 Dec;190(6):2081-5. doi: 10.1016/j.juro.2013.06.009. Epub 2013 Jun 11.

PMID:
23764076
3.

Assessment and management of renal impairment in chemotherapy for urogenital cancer.

Kawai K, Ichioka D, Inai H, Miyazaki J, Nishiyama H.

Jpn J Clin Oncol. 2013 Nov;43(11):1055-63. doi: 10.1093/jjco/hyt132. Epub 2013 Sep 12. Review.

4.

Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.

Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW.

Cochrane Database Syst Rev. 2013 Oct 8;(10):CD008944. doi: 10.1002/14651858.CD008944.pub2. Review.

PMID:
24101439
5.

Long-term nephrotoxicity in adult survivors of childhood cancer.

Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, van den Heuvel-Eibrink MM.

Clin J Am Soc Nephrol. 2013 Jun;8(6):922-9. doi: 10.2215/CJN.09980912. Epub 2013 Feb 14.

6.

Effect of testicular germ cell tumor therapy on renal function.

Cost NG, Adibi M, Lubahn JD, Romman A, Raj GV, Sagalowsky AI, Margulis V.

Urology. 2012 Sep;80(3):641-8. doi: 10.1016/j.urology.2012.04.064. Epub 2012 Jul 26.

PMID:
22840865
7.

Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.

Utsumi T, Kawamura K, Imamoto T, Nagano H, Tanaka T, Kamiya N, Nihei N, Naya Y, Suzuki H, Ichikawa T.

Int J Urol. 2013 Jul;20(7):685-91. doi: 10.1111/iju.12029. Epub 2012 Nov 27.

8.

Comparison of postoperative estimated glomerular filtration rate between kidney donors and radical nephrectomy patients, and risk factors for postoperative chronic kidney disease.

Lee SH, Kim DS, Cho S, Kim SJ, Kang SH, Park J, Park SY, Chang SG, Jeon SH.

Int J Urol. 2015 Jul;22(7):674-8. doi: 10.1111/iju.12784. Epub 2015 May 26.

9.

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.

Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD.

Clin Genitourin Cancer. 2012 Mar;10(1):15-20. doi: 10.1016/j.clgc.2011.10.004. Epub 2011 Nov 29.

PMID:
22130294
10.

Editorial comment from Dr Miki to risk factors for chronic kidney disease after chemotherapy for testicular cancer.

Miki T.

Int J Urol. 2013 Jul;20(7):723. doi: 10.1111/iju.12036. Epub 2012 Nov 28. No abstract available.

11.

Editorial comment from Dr Tanaka to risk factors for chronic kidney disease after chemotherapy for testicular cancer.

Tanaka T.

Int J Urol. 2013 Jul;20(7):722-3. doi: 10.1111/iju.12026. Epub 2012 Nov 27. No abstract available.

12.

Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fosså SD.

J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95. doi: 10.1093/jnci/djp413. Epub .

13.

Incidence and risk factors of chronic kidney disease in korean patients with t1a renal cell carcinoma before and after radical or partial nephrectomy.

Kim SH, Lee SE, Hong SK, Jeong CW, Park YH, Kim YJ, Kang SH, Hong SH, Choi WS, Byun SS.

Jpn J Clin Oncol. 2013 Dec;43(12):1243-8. doi: 10.1093/jjco/hyt149. Epub 2013 Nov 5.

14.

Serum creatinine and cholesterol levels of testicular cancer patients in long-term follow up.

Hisamatsu E, Kawai K, Hinotsu S, Miyanaga N, Shimazui T, Akaza H.

Int J Urol. 2005 Aug;12(8):751-6.

15.

A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.

Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, Roberts JT, Fossa SD, Dearnaley DP, Lallemand E, Stenning SP; MRC Testicular Tumour Working Party.

Br J Cancer. 2000 Dec;83(12):1623-9.

16.

Uric acid levels correlate with baseline renal function and high levels are a potent risk factor for postoperative chronic kidney disease in patients with renal cell carcinoma.

Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

J Urol. 2013 Apr;189(4):1249-54. doi: 10.1016/j.juro.2012.11.043. Epub 2012 Nov 13.

PMID:
23159461
17.

The effect of cisplatin on renal function in patients with testicular tumours.

MacLeod PM, Tyrell CJ, Keeling DH.

Clin Radiol. 1988 Mar;39(2):190-2.

PMID:
3128418
18.

Glomerular filtration rate and prevalence of chronic kidney disease in Wilms' tumour survivors.

Stefanowicz J, Kosiak M, Romanowicz G, Owczuk R, Adamkiewicz-Drożyńska E, Balcerska A.

Pediatr Nephrol. 2011 May;26(5):759-66. doi: 10.1007/s00467-011-1759-3. Epub 2011 Jan 29.

19.

Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.

Perkins RM, Kirchner HL, Hartle JE, Bucaloiu ID.

Clin Nephrol. 2013 Oct;80(4):256-62. doi: 10.5414/CN107905.

PMID:
23993165
20.

Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors.

Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH, Lieverst JA, Bökenkamp A, Koning CC, Oldenburger F, Wilde JC, van Leeuwen FE, Caron HN, Kremer LC.

Clin J Am Soc Nephrol. 2012 Sep;7(9):1416-27. Epub 2012 Jul 19.

Items per page

Supplemental Content

Write to the Help Desk